-
公开(公告)号:BRPI0617884A2
公开(公告)日:2011-08-09
申请号:BRPI0617884
申请日:2006-10-27
Applicant: ABBOTT LAB
Inventor: GOMTSYAN ARTHUR R , BAYBURT EROL K , KOENIG JOHN R , MARSH KENNAN C , SCHMIDT ROBERT G JR , LEE CHIH-HUNG , WANG WEILI , DAANEN JEROME F , BROWN BRIAN S
IPC: C07D231/56 , A61K31/416 , A61P13/00 , C07D407/12
Abstract: Compounds of formula (I) wherein A, R1, R2, and R3 are defined in the specification, and which are useful as therapeutic compounds particularly for treating disorders or conditions associated with inflammation, pain, bladder overactivity, urinary incontinence, and other disorders caused by or exacerbated by TRPV1.
-
公开(公告)号:SI1658269T1
公开(公告)日:2009-04-30
申请号:SI200430995
申请日:2004-06-10
Applicant: ABBOTT LAB
Inventor: GOMTSYAN ARTHUR , BAYBURT EROL K , LEE CHIH-HUNG , KOENIG JOHN R , SCHMIDT ROBERT , LUKIN KIRILL , CHAMBOURNIER GILLES , HSU MARGARET , LEANNA M ROBERT , CINK RUSSEL D
IPC: C07D217/00 , A61K31/00 , A61P13/00 , A61P13/10 , C07C211/00 , C07D217/02 , C07D231/00 , C07D231/56 , C07D401/00 , C07D401/12 , C07D403/00 , C07D403/12
-
公开(公告)号:AT420644T
公开(公告)日:2009-01-15
申请号:AT03716014
申请日:2003-02-11
Applicant: ABBOTT LAB
Inventor: LEE CHIH-HUNG , BAYBURT EROL , DIDOMENICO STANLEY JR , DRIZIN IRENE , GOMTSYAN ARTHUR , KOENIG JOHN R , PERNER RICHARD , SCHMIDT ROBERT G , TURNER SEAN C , WHITE TAMMIE , ZHENG GUO
IPC: A61K31/502 , A61K31/404 , A61K31/416 , A61K31/47 , A61K31/472 , A61K31/496 , A61K31/5377 , A61K31/541 , C07D209/08 , C07D217/02 , C07D217/22 , C07D217/24 , C07D217/26 , C07D231/56 , C07D237/28 , C07D401/12 , C07D405/12 , C07D521/00
-
公开(公告)号:CA2743534A1
公开(公告)日:2005-02-24
申请号:CA2743534
申请日:2004-08-04
Applicant: ABBOTT LAB
Inventor: LEE CHIH-HUNG , BAYBURT EROL K , DIDOMENICO STANLEY JR , DRIZIN IRENE , GOMTSYAN ARTHUR R , KOENIG JOHN R , PERNER RICHARD J , SCHMIDT ROBERT G JR , TURNER SEAN C , WHITE TAMMIE K , ZHENG GUO ZHU
IPC: C07D231/56 , A61K31/416 , A61K31/439 , A61K31/46 , A61K31/472 , A61K31/55 , A61P13/10 , C07D217/02 , C07D401/12 , C07D403/12 , C07D451/02 , C07D471/08
Abstract: Compounds of formula (I) (see formula (I)) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.
-
公开(公告)号:CA2534542A1
公开(公告)日:2005-02-24
申请号:CA2534542
申请日:2004-08-04
Applicant: ABBOTT LAB
Inventor: WHITE TAMMIE K , ZHENG GUO ZHU , TURNER SEAN C , SCHMIDT ROBERT G JR , DRIZIN IRENE , PERNER RICHARD J , KOENIG JOHN R , GOMTSYAN ARTHUR R , DIDOMENICO STANLEY JR , BAYBURT EROL K , LEE CHIH-HUNG
IPC: C07D217/24 , A61K31/47 , A61K31/472 , A61K31/496 , A61K31/5377 , C07D209/08 , C07D217/02 , C07D217/22 , C07D217/26 , C07D231/56 , C07D237/28 , C07D401/12 , C07D403/12 , C07D405/12 , C07D451/02 , C07D521/00
Abstract: Compounds of Formula (I), are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.
-
公开(公告)号:ZA201102735B
公开(公告)日:2012-12-27
申请号:ZA201102735
申请日:2011-04-12
Applicant: ABBOTT LAB
Inventor: GOMTSYAN ARTHUR R , FERNANDO DILNIE P , HSU MARGARET CHI-PING , KOENIG JOHN R , PERNER RICHARD J , LEE CHIH-HUNG
IPC: A61K20060101 , A61P20060101 , C07D20060101
Abstract: The present invention is directed to compounds of formula (I) wherein variables W, X, Y, D, A, n, R1, R2 and R9 are as defined in the description.
-
公开(公告)号:AU2010257277A1
公开(公告)日:2011-01-13
申请号:AU2010257277
申请日:2010-12-17
Applicant: ABBOTT LAB
Inventor: GOMTSYAN ARTHUR , LEE CHIH-HUNG , CHAMBOURNIER GILLES , KOENIG JOHN R , LUKIN KIRILL , LEANNA M ROBERT , HSU MARGARET , SCHMIDT ROBERT , CINK RUSSEL D
IPC: A61P13/10 , C07D217/02 , C07D231/56 , C07D401/12 , C07D403/12
Abstract: The present invention discloses novel compounds of general formula (I), or a pharmaceutically acceptable salt thereof (in which X 1 - X 5 , R 5 - R 8b , Z 1 - Z 2 and Ar 1 are defined herein), pharmaceutical compositions including those compounds and a process for making those compounds. The compounds of formula (I) are useful for treating pain, bladder overreactivity, urinary incontinence, inflammatory hyperalgesia by inhibiting the VR1 receptor in mammals.
-
公开(公告)号:MX2010004495A
公开(公告)日:2010-05-05
申请号:MX2010004495
申请日:2008-10-25
Applicant: ABBOTT LAB
Inventor: VASUDEVAN ANIL , KORT MICHAEL E , BAYBURT EROL K , KOENIG JOHN R , SCHMIDT ROBERT G , DIDOMENICO STANLEY JR , GOMTSYAN ARTHUR R , PERNER RICHARD J , DAANEN JEROME F , KYM PHILIP R , VOIGHT ERIC
IPC: C07D263/48 , A61K31/421 , A61P29/00 , C07D413/04 , C07D413/12
Abstract: Se describen compuestos de la fórmula (I), en donde R1, R2, R4, y W son como se describe en la descripción y son antagonistas de TRPV1 con penetración en el sistema nervioso central (CNS). Se describen también composiciones que comprenden dichos compuestos y métodos para tratar condiciones y trastornos utilizando dichos compuestos y composiciones. (Ver fórmula I).
-
公开(公告)号:CA2702976A1
公开(公告)日:2009-04-30
申请号:CA2702976
申请日:2008-10-25
Applicant: ABBOTT LAB
Inventor: PERNER RICHARD J , KOENIG JOHN R , DIDOMENICO STANLEY JR , BAYBURT EROL K , DAANEN JEROME F , GOMTSYAN ARTHUR R , KORT MICHAEL E , KYM PHILIP R , VASUDEVAN ANIL , SCHMIDT ROBERT G , VOIGHT ERIC
IPC: C07D263/48 , A61K31/421 , A61P29/00 , C07D413/04 , C07D413/12
Abstract: Compounds of formula (I) wherein R1, R2, R4, and W are defined in the description are TRPV1 antagonists with CNS penetration. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
-
20.
公开(公告)号:ES2315704T3
公开(公告)日:2009-04-01
申请号:ES04780017
申请日:2004-08-04
Applicant: ABBOTT LAB
Inventor: BAYBURT EROL K , DIDOMENICO STANLEY JR , DRIZIN IRENE , GOMTSYAN ARTHUR R , KOENIG JOHN R , PENNER RICHARD J
IPC: C07D217/24 , A61K31/47 , A61K31/472 , A61K31/496 , A61K31/5377 , C07D209/08 , C07D217/02 , C07D217/22 , C07D217/26 , C07D231/56 , C07D237/28 , C07D401/12 , C07D403/12 , C07D405/12 , C07D451/02 , C07D521/00
Abstract: Un compuesto de formula (I) (Ver fórmula) o una sal farmacéuticamente aceptable del mismo, donde X1 es CR1; X2 es N; X3 es NR3; X5 es N; Z1 es O; Z2 es NH; L se selecciona del grupo que consiste en alquenileno, alquileno, alquinileno, cicloalquileno, -(CH2)mO(CH2)n-, y N(RY), donde el extremo izquierdo de -(CH2)mO(CH2)n- está unido a Z2 y el extremo derecho está unido a R9; m y n son cada uno independientemente 0-6; RY se selecciona del grupo que consiste en hidrógeno y alquilo; R1, R3, R5, R6, y R7 se seleccionan cada uno independientemente del grupo que consiste en hidrógeno, alquenilo, alcoxi, alcoxialcoxi, alcoxialquilo, alcoxicarbonilo, alcoxicarbonilalquilo, alquilo, alquilcarbonilo, alquilcarbonilalquilo, alquil-carboniloxi, alquiltio, alquinilo, carboxi, carboxialquilo, ciano, cianoalquilo, cicloalquilo, cicloalquilalquilo, formilo, formilalquilo, haloalcoxi, haloalquilo, haloalquiltio, halógeno, hidroxi, hidroxialquilo, mercapto, mercaptoalquilo, nitro, (CF3)2(HO)C-, -NRAS(O)2RB, -S(O)2ORA, -S(O)2RB, -NZAZB, (NZAZB)alquilo, (NZAZB)carbonilo, (NZAZB)carbonilalquilo y (NZAZB)sulfonilo, donde ZA y ZB se seleccionan cada uno independientemente del grupo que consiste en hidrógeno, alquilo, alquilcarbonilo, formilo, arilo, y arilalquilo; RA se selecciona del grupo que consiste en hidrógeno y alquilo; RB se selecciona del grupo que consiste en alquilo, arilo, y arilalquilo; R8a se selecciona del grupo que consiste en hidrógeno y alquilo; R9 se selecciona del grupo que consiste en arilo y heterociclo; donde...
-
-
-
-
-
-
-
-
-